These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 36453542)

  • 41. Targeted multifunctional lipid-based nanocarriers for image-guided drug delivery.
    Koning GA; Krijger GC
    Anticancer Agents Med Chem; 2007 Jul; 7(4):425-40. PubMed ID: 17630918
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeted Codelivery of an Antigen and Dual Agonists by Hybrid Nanoparticles for Enhanced Cancer Immunotherapy.
    Zhang L; Wu S; Qin Y; Fan F; Zhang Z; Huang C; Ji W; Lu L; Wang C; Sun H; Leng X; Kong D; Zhu D
    Nano Lett; 2019 Jul; 19(7):4237-4249. PubMed ID: 30868883
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Polymer-Lipid Hybrid Nanoparticles: A Next-Generation Nanocarrier for Targeted Treatment of Solid Tumors.
    Rizwanullah M; Alam M; Harshita ; Mir SR; Rizvi MMA; Amin S
    Curr Pharm Des; 2020; 26(11):1206-1215. PubMed ID: 31951163
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Delivery of Liver-Specific miRNA-122 Using a Targeted Macromolecular Prodrug toward Synergistic Therapy for Hepatocellular Carcinoma.
    Ning Q; Liu YF; Ye PJ; Gao P; Li ZP; Tang SY; He DX; Tang SS; Wei H; Yu CY
    ACS Appl Mater Interfaces; 2019 Mar; 11(11):10578-10588. PubMed ID: 30802029
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Utilization of Polymer-Lipid Hybrid Nanoparticles for Targeted Anti-Cancer Therapy.
    Mohanty A; Uthaman S; Park IK
    Molecules; 2020 Sep; 25(19):. PubMed ID: 32977707
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combination Cancer Therapy Using Multifunctional Liposomes.
    Jain A; Tiwari A; Verma A; Saraf S; Jain SK
    Crit Rev Ther Drug Carrier Syst; 2020; 37(2):105-134. PubMed ID: 32865902
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Advancements and prospects of lipid-based nanoparticles: dual frontiers in cancer treatment and vaccine development.
    Shaw I; Boafo GF; Ali YS; Liu Y; Mlambo R; Tan S; Chen C
    J Microencapsul; 2024 May; 41(3):226-254. PubMed ID: 38560994
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pulmonary Codelivery of Doxorubicin and siRNA by pH-Sensitive Nanoparticles for Therapy of Metastatic Lung Cancer.
    Xu C; Wang P; Zhang J; Tian H; Park K; Chen X
    Small; 2015 Sep; 11(34):4321-33. PubMed ID: 26136261
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Doxorubicin and siRNA Codelivery via Chitosan-Coated pH-Responsive Mixed Micellar Polyplexes for Enhanced Cancer Therapy in Multidrug-Resistant Tumors.
    Butt AM; Amin MC; Katas H; Abdul Murad NA; Jamal R; Kesharwani P
    Mol Pharm; 2016 Dec; 13(12):4179-4190. PubMed ID: 27934479
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Codelivery of CPT and siPHB1 with GSH/ROS Dual-Responsive Hybrid Nanoparticles Based on a [12]aneN
    Liang YX; Sun XY; Xu DZ; Gao YN; Tang Q; Lu ZL; Liu Y
    ACS Appl Bio Mater; 2024 May; 7(5):3202-3214. PubMed ID: 38651918
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Recent Advances in siRNA Delivery Systems for Prostate Cancer Therapy.
    Aghamiri S; Raee P; Shahmohamadnejad S; Shabani S; Ghorbani J; Sameni M; Ebrahimi MT
    Curr Pharm Biotechnol; 2022; 23(4):579-593. PubMed ID: 34132181
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Overcoming cancer multidrug resistance by codelivery of doxorubicin and verapamil with hydrogel nanoparticles.
    Qin M; Lee YE; Ray A; Kopelman R
    Macromol Biosci; 2014 Aug; 14(8):1106-15. PubMed ID: 24771682
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Developing Biodegradable Lipid Nanoparticles for Intracellular mRNA Delivery and Genome Editing.
    Qiu M; Li Y; Bloomer H; Xu Q
    Acc Chem Res; 2021 Nov; 54(21):4001-4011. PubMed ID: 34668716
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Codelivery of adavosertib and olaparib by tumor-targeting nanoparticles for augmented efficacy and reduced toxicity.
    Wang W; Xiong Y; Hu X; Lu F; Qin T; Zhang L; Guo E; Yang B; Fu Y; Hu D; Fan J; Qin X; Liu C; Xiao R; Chen G; Li Z; Sun C
    Acta Biomater; 2023 Feb; 157():428-441. PubMed ID: 36549633
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tumour targeting: biological factors and formulation advances in injectable lipid nanoparticles.
    Shenoy VS; Vijay IK; Murthy RS
    J Pharm Pharmacol; 2005 Apr; 57(4):411-22. PubMed ID: 15831200
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Advances in Hybrid Vesicular-based Drug Delivery Systems: Improved Biocompatibility, Targeting, Therapeutic Efficacy and Pharmacokinetics of Anticancer Drugs.
    Setia A; Sahu RK; Ray S; Widyowati R; Ekasari W; Saraf S
    Curr Drug Metab; 2022; 23(9):757-780. PubMed ID: 35761494
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Targeting death receptors for drug-resistant cancer therapy: Codelivery of pTRAIL and monensin using dual-targeting and stimuli-responsive self-assembling nanocomposites.
    Xu F; Zhong H; Chang Y; Li D; Jin H; Zhang M; Wang H; Jiang C; Shen Y; Huang Y
    Biomaterials; 2018 Mar; 158():56-73. PubMed ID: 29304403
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lipid-Coated Nanosized Drug Delivery Systems for an Effective Cancer Therapy.
    Esim O; Hascicek C
    Curr Drug Deliv; 2021; 18(2):147-161. PubMed ID: 32394833
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nanomedicine for cancer: lipid-based nanostructures for drug delivery and monitoring.
    Namiki Y; Fuchigami T; Tada N; Kawamura R; Matsunuma S; Kitamoto Y; Nakagawa M
    Acc Chem Res; 2011 Oct; 44(10):1080-93. PubMed ID: 21786832
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dermal Delivery of Lipid Nanoparticles: Effects on Skin and Assessment of Absorption and Safety.
    Pinto F; Fonseca LP; de Barros DPC
    Adv Exp Med Biol; 2022; 1357():83-114. PubMed ID: 35583641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.